IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Stifel raised the firm’s price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management’s ability to provide a preliminary mid-FY25 update ...

Igm Biosciences ( ($IGMS) ) has released its Q3 earnings. Here is a breakdown of the information Igm Biosciences presented to ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target ...

Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Igm Biosciences faces significant risks that could adversely impact its business and financial ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective increased by Royal Bank of Canada from $17.00 to $20.00 in a research note published on Friday morning, Benzinga reports.

Since it has a market capitalisation of US$939m, IGM Biosciences' US$176m in cash burn equates to about 19% of its market value. As a result, we'd venture that the company could raise more cash for ...

The company’s 50 day moving average is $14.23 and its 200-day moving average is $10.74. IGM Biosciences has a 12 month low of $3.81 and a 12 month high of $22.50. The firm has a market cap of $1 ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on developing treatments for autoimmune diseases, has recently undergone a significant strategic shift that has caught the ...